BioSpace

Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance

Novartis is discontinuing a neurodegeneration alliance with BioArctic in which the companies aimed to develop a drug candidate that could cross the blood-brain barrier.

By BioSpace

1 min read
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights